Sandoz Achieves 3% Net Sales Growth in Q1 2025, Eyes Further Biosimilar Launches

Sandoz Group Ltd ( (CH:SDZ) ) just unveiled an announcement.

Sandoz reported a 3% increase in net sales for Q1 2025, reaching USD 2,480 million, driven by strong performance in Europe and a growing biosimilar pipeline. The company anticipates further biosimilar launches in the second half of the year, aiming for mid single-digit net sales growth and a core EBITDA margin of around 21% for the full year. Despite challenges such as price erosion and recent US tariffs, Sandoz remains confident in delivering affordable medicines and sustainable growth.

More about Sandoz Group Ltd

Sandoz is a global leader in generic and biosimilar medicines, focusing on pioneering access for patients. With a workforce of over 20,000 people from 100 nationalities, Sandoz provides more than 900 million patient treatments, contributing significantly to global healthcare savings. The company offers a diverse portfolio of approximately 1,300 products addressing various diseases, from common colds to cancer. Headquartered in Basel, Switzerland, Sandoz has a rich history of breakthroughs dating back to 1886.

YTD Price Performance: 8.66%

Average Trading Volume: 3,798

Technical Sentiment Signal: Strong Sell

Current Market Cap: $19.28B

Find detailed analytics on SDZ stock on TipRanks’ Stock Analysis page.